Trials / Recruiting
RecruitingNCT06030076
A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
A Non-interventional, Prospective Cohort, Multicentre, Real-world Evidence Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis in Austria and Switzerland
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Almirall, S.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main aim of this study is to assess the effects of switching from another biologic to tildrakizumab on patient-reported outcomes and to assess psoriasis intensity, patient's quality of life prior and after switching and the individual rationales for switching biologics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tildrakizumab | As provided in real-world clinical practice. |
Timeline
- Start date
- 2023-09-06
- Primary completion
- 2025-10-01
- Completion
- 2025-10-01
- First posted
- 2023-09-08
- Last updated
- 2025-01-29
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT06030076. Inclusion in this directory is not an endorsement.